$28.41
0.50%
NYSE, Mon, Nov 25 2024
ISIN
US2289031005
Symbol
CRY

CryoLife Stock price

$28.41
+1.94 7.33% 1M
+4.63 19.47% 6M
+10.53 58.89% YTD
+10.90 62.25% 1Y
+9.57 50.80% 3Y
+3.32 13.23% 5Y
+18.39 183.53% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.14 0.50%
ISIN
US2289031005
Symbol
CRY
Sector

Key metrics

Market capitalization $1.19b
Enterprise Value $1.50b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 136.23
EV/Sales (TTM) EV/Sales 3.89
P/S ratio (TTM) P/S ratio 3.09
P/B ratio (TTM) P/B ratio 3.91
Revenue growth (TTM) Revenue growth 13.29%
Revenue (TTM) Revenue $384.90m
EBIT (operating result TTM) EBIT $63.47m
Free Cash Flow (TTM) Free Cash Flow $11.00m
Cash position $56.17m
EPS (TTM) EPS $-0.03
P/E forward 2,130.80
P/S forward 3.04
EV/Sales forward 3.82
Short interest 11.11%
Show more

Is CryoLife a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

CryoLife Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CryoLife forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a CryoLife forecast:

Buy
100%

Financial data from CryoLife

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
385 385
13% 13%
100%
- Direct Costs 152 152
12% 12%
40%
233 233
14% 14%
60%
- Selling and Administrative Expenses 117 117
12% 12%
30%
- Research and Development Expense 29 29
2% 2%
7%
87 87
113% 113%
23%
- Depreciation and Amortization 24 24
5% 5%
6%
EBIT (Operating Income) EBIT 63 63
246% 246%
16%
Net Profit -0.85 -0.85
97% 97%
0%

In millions USD.

Don't miss a Thing! We will send you all news about CryoLife directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Head office United States
CEO James Mackin
Employees 1,500
Founded 1984
Website www.artivion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today